CHN2: A Potential Drug Target and Biomarker for尾-Chimerin (G1124)

Target Name: CHN2

NCBI ID: G1124

CHN2

CHN2: A Potential Drug Target and Biomarker for尾-Chimerin

Abstract:

尾-chimerin is a glycoprotein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. CHN2, a specific 尾-chimerin isoform, has been shown to have unique functional properties that make it an attractive candidate for drug development. This article will summarize the current research on CHN2 and its potential as a drug target and biomarker.

Introduction:

尾-chimerin is a glycoprotein that consists of two heavy chains and two light chains. It is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. 尾-chimerin has unique functional properties due to the presence of the N- and C-terminus, which are rich in conserved sequence and charge.

CHN2: A Specific 尾-Chimerin Isoform

CHN2 is a specific 尾-chimerin isoform that is expressed in various tissues and organs, including brain, heart, liver, and muscle. It is characterized by its unique molecular structure and function, which have made it an attractive candidate for drug development.

Functional Studies of CHN2

CHN2 has been shown to have unique functional properties due to its conserved N- and C-terminus. The N-terminus of CHN2 contains a glycine-rich region that is known to have conserved sequences and can bind various ligands, such as Peptide or protein molecule. The C-terminus of CHN2 is rich in electrostatic potential and has been shown to have a unique conformation that is different from other 尾-chimerins.

In addition to its unique N- and C-terminus, CHN2 has been shown to have other unique functional properties, including:

1. CHN2 is a glycoprotein that has a low molecular weight, which makes it easy to transport and process in the body.
2. CHN2 can be used as a bioremediable agent, as it can be easily eliminated from the body by the kidneys.
3. CHN2 has a unique isoelectric point (pI) that makes it an attractive candidate for drug targeting.
4. CHN2 has been shown to have a unique binding affinity for various ligands, such as peptides or protein molecules, indicating that it has unique biological activities.

Potential Drug Target and Biomarker

CHN2 has been shown to have a unique functional profile that makes it an attractive candidate for drug targeting and biomarker research. Its low molecular weight, electrostatic potential, and unique isoelectric point make it an interesting target for small molecule inhibitors or monoclonal antibodies.

In addition, CHN2 has been shown to have a unique expression pattern in various tissues and organs, which makes it an attractive candidate for biomarker research. Its expression patterns in brain and heart may indicate its potential as a drug target for neurodegenerative disorders.

Conclusion:

CHN2 is a unique 尾-chimerin isoform that has been shown to have unique functional properties and potential as a drug target and biomarker. Its low molecular weight, electrostatic potential, and unique isoelectric point make it an interesting target for small molecule inhibitors or monoclonal antibodies . Its unique expression pattern in various tissues and organs may indicate its potential as a biomarker for various diseases. Further research is needed to fully understand its potential as a drug target and biomarker.

Protein Name: Chimerin 2

Functions: GTPase-activating protein for p21-rac. Insufficient expression of beta-2 chimaerin is expected to lead to higher Rac activity and could therefore play a role in the progression from low-grade to high-grade tumors

The "CHN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets